Literature DB >> 25787918

A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies.

Brigitte Schlegelberger1, Hans Kreipe2, Ulrich Lehmann2, Doris Steinemann1, Tim Ripperger1, Gudrun Göhring1, Kathrin Thomay1, Andreas Rump3, Nataliya Di Donato3, Meinolf Suttorp4.   

Abstract

Here we report on a child with Li-Fraumeni syndrome with a de novo TP53 mutation c.818G>A, who developed three malignancies at the age of 4 months, 4 and 5 years, respectively. We show that (i) in the choroid plexus carcinoma, the germline mutation was detected in a homozygous state due to copy-neutral LOH/uniparental disomy, (ii) in the secondary AML, a complex karyotype led to loss of the wild-type TP53 allele, (iii) in the Wilms tumor, the somatic mutation c.814G>A led to compound heterozygosity. The findings show that the complete inactivation of TP53 by different mechanisms is an important step towards tumorigenesis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Li-Fraumeni syndrome; TP53; choroid plexus carcinoma; leukemia; sarcoma; uniparental disomy (UPD)

Mesh:

Substances:

Year:  2015        PMID: 25787918     DOI: 10.1002/pbc.25486

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.

Authors:  Rolando A R Villacis; Tatiane R Basso; Luisa M Canto; Maísa Pinheiro; Karina M Santiago; Juliana Giacomazzi; Cláudia A A de Paula; Dirce M Carraro; Patrícia Ashton-Prolla; Maria I Achatz; Silvia R Rogatto
Journal:  J Mol Med (Berl)       Date:  2017-01-16       Impact factor: 4.599

2.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 3.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

4.  Acute myeloid leukemia with TP53 germ line mutations.

Authors:  Armin Zebisch; Ridhima Lal; Marian Müller; Karin Lind; Karl Kashofer; Michael Girschikofsky; David Fuchs; Albert Wölfler; Jochen B Geigl; Heinz Sill
Journal:  Blood       Date:  2016-09-12       Impact factor: 22.113

5.  Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism.

Authors:  Dawid Walerych; Magdalena Pruszko; Lukasz Zyla; Michalina Wezyk; Katarzyna Gaweda-Walerych; Alicja Zylicz
Journal:  Oncotarget       Date:  2018-08-10

6.  Overview of the Clinical Features of Li-Fraumeni Syndrome and the Current European ERN GENTURIS Guideline.

Authors:  Christian Peter Kratz; Verena Steinke-Lange; Isabel Spier; Stefan Aretz; Evelin Schröck; Elke Holinski-Feder
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-10-25       Impact factor: 2.915

Review 7.  Mutant p53: One, No One, and One Hundred Thousand.

Authors:  Dawid Walerych; Kamil Lisek; Giannino Del Sal
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

Review 8.  Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies.

Authors:  Brigitte Schlegelberger; Cristina Mecucci; Marcin Wlodarski
Journal:  Fam Cancer       Date:  2021-05-31       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.